Compare Abeona Therapeutics Inc (ABEO) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Mercadolibre Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Mercadolibre Inc trades at $1,805.81 (market cap $91.94B). The key difference: Mercadolibre Inc is far larger — about 246.3× Abeona Therapeutics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | MELI | |
|---|---|---|
Market Cap | $373.32M | $91.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $2.51K |
52-Week Low | $4.17 | $1.55K |
Enterprise Value | $228.22M | $98.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MercadoLibre (MELI) trades at $1,813.61, up 2.85% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with robust revenue growth of 49% in Q1 2026 and expanding cash flow generation. Analyst consensus remains strongly positive with a $2,230 price target, though margin compression from aggressive investments presents near-term challenges.
MELI offers significant growth potential as Latin America's e-commerce leader, but faces execution risks from margin pressure and legal investigations. The stock trades at premium valuations (P/E 47.66) requiring sustained high growth to justify current levels. Institutional support remains strong with 71.9% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
